Evidence map›Paper›PMID 33179113›Full record

ArticleMolecular medicine reports2021

Activation of activin/Smad2 and 3 signaling pathway and the potential involvement of endothelial‑mesenchymal transition in the valvular damage due to rheumatic heart disease.

Shenglin Xian, Ang Chen, Xiaodan Wu, Chuanghong Lu, Yunjiao Wu, Feng Huang, Zhiyu Zeng

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Valve biology and rheumatic heart disease pathogenesis.Nature cardiovascular research · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Frontiers in cellular and infection microbiology · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Endothelial-Mesenchymal Transition in Cardiovascular Disease.Arteriosclerosis, thrombosis, and vascular biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shenglin XianDepartment of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Ang ChenDepartment of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Xiaodan WuDepartment of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Chuanghong LuDepartment of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Yunjiao WuDepartment of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Feng HuangDepartment of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Zhiyu ZengDepartment of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Guangxi Medical University · CNFirst Affiliated Hospital of GuangXi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatic heart disease (RHD) is an autoimmune disease caused by rheumatic fever following group A hemolytic streptococcal infection and primarily affects the mitral valve. RHD is currently a major global health problem. However, the exact pathological mechanisms associated with RHD‑induced cardiac valve damage remain to be elucidated. The endothelial‑mesenchymal transition (EndMT) serves a key role in a number of diseases with an important role in cardiac fibrosis and the activin/Smad2 and 3 signaling pathway is involved in regulating the EndMT. Nevertheless, there are no studies to date, to the best of the authors' knowledge, investigating the association between RHD and EndMT. Thus, the aim of the current study was to investigate the potential role of EndMT in cardiac valve damage and assess whether activin/Smad2 and 3 signaling was activated during RHD‑induced valvular injury in a rat model of RHD induced by inactivated Group A streptococci and complete Freund's adjuvant. Inflammation and fibrosis were assessed by hematoxylin and eosin and Sirius red staining. Serum cytokine and rheumatoid factor levels were measured using ELISA kits. Expression levels of activin/Smad2 and 3 signaling pathway‑related factors [activin A, Smad2, Smad3, phosphorylated (p‑)Smad2 and p‑Smad3], EndMT‑related factors [lymphoid enhancer factor‑1 (LEF‑1), Snail1, TWIST, zinc finger E‑box‑binding homeobox (ZEB)1, ZEB2, α smooth muscle actin (α‑SMA) and type I collagen α 1 (COL1A1)], apoptosis‑related markers (BAX and cleaved caspase‑3) and valvular inflammation markers (NF‑κB and p‑NF‑κB) were detected using reverse transcription‑quantitative PCR and western blot analyses. Compared with the control group, the degree of valvular inflammation and fibrosis, serum levels of IL‑6, IL‑17, TNF‑α and expression of apoptosis‑related markers (BAX and cleaved caspase‑3) and valvular inflammation marker (p‑NF‑κB), activin/Smad2 and 3 signaling pathway‑related factors (activin A, p‑Smad2 and p‑Smad3), EndMT‑related factors (LEF‑1, Snail1, TWIST, ZEB 1, ZEB2, α‑SMA and COL1A1) were significantly increased in the RHD group. These results suggested that the activin/Smad2 and 3 signaling pathway was activated during the development of valvular damage caused by RHD and that the EndMT is involved in RHD‑induced cardiac valve damage.

Indexed as

ActivinsAnimalsDisease Models, AnimalFemaleFibrosisFreund's AdjuvantMitral ValveRatsRheumatic Heart DiseaseSignal TransductionSmad2 ProteinSmad3 ProteinStreptococcus pyogenesActivinsFreund's AdjuvantSmad2 ProteinSmad2 protein, ratSmad3 ProteinSmad3 protein, ratactivinendothelial‑mesenchymal transitionrheumatic heart diseaseSmad2Smad3valvular damage

Identifiers

PMID33179113
PMCPMC7673319
OpenAlexW3095858614

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.